Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain.
about
Regional tau deposition and subregion atrophy of medial temporal structures in early Alzheimer's disease: A combined positron emission tomography/magnetic resonance imaging study.Specific protein biomarker patterns for Alzheimer's disease: improved diagnostics in progress.The emerging role of PET imaging in dementia.18 F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study.Head to head comparison of [(18)F] AV-1451 and [(18)F] THK5351 for tau imaging in Alzheimer's disease and frontotemporal dementia.Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains.The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases.New advances in tau imaging in parkinsonism.Multimodal correlation of dynamic [18F]-AV-1451 perfusion PET and neuronal hypometabolism in [18F]-FDG PET.Flortaucipir tau PET imaging in semantic variant primary progressive aphasia.Characterization of the radiosynthesis and purification of [18F]THK-5351, a PET ligand for neurofibrillary tau.In Vivo Tau Imaging for a Diagnostic Platform of Tauopathy Using the rTg4510 Mouse Line.Tau Diagnostics and Clinical Studies.Preclinical Evaluation of (18)F-RO6958948, (11)C-RO6931643 and (11)C-RO6924963 as Novel Radiotracers for Imaging Aggregated Tau in AD with Positron Emission Tomography.Small-molecule PET Tracers for Imaging Proteinopathies.Tau Positron Emission Tomography Imaging in Degenerative Parkinsonisms.In vivo [18F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease.MAO-B Inhibitors Do Not Block In Vivo Flortaucipir([(18)F]-AV-1451) Binding.Tau Filaments and the Development of Positron Emission Tomography Tracers.Targeting Alzheimer's Disease at the Right Time and the Right Place: Validation of a Personalized Approach to Diagnosis and Treatment.PET imaging of tau protein targets: a methodology perspective.Neuroimaging in Dementia.The Place of PET to Assess New Therapeutic Effectiveness in Neurodegenerative Diseases.Molecular imaging: What is right and what is an illusion?Large inter- and intra-case variability of first generation tau PET ligand binding in neurodegenerative dementias.Comparison of 18F-T807 and 18F-THK5117 PET in a Mouse Model of Tau Pathology.Role of Neuroimaging as a Biomarker for Neurodegenerative Diseases.18F-AV-1451 in Parkinson's Disease with and without dementia and in Dementia with Lewy Bodies.Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding.Neuroimaging-pathological correlations of [18F]THK5351 PET in progressive supranuclear palsy.Clinical Routine FDG-PET Imaging of Suspected Progressive Supranuclear Palsy and Corticobasal Degeneration: A Gatekeeper for Subsequent Tau-PET Imaging?The development and validation of tau PET tracers: current status and future directionsIn vivo quantification of neurofibrillary tangles with [F]MK-6240Imaging Protein Misfolding in the Brain Using β-Sheet LigandsInvolvement of the Precuneus/Posterior Cingulate Cortex Is Significant for the Development of Alzheimer's Disease: A PET (THK5351, PiB) and Resting fMRI StudyThe Binding of BF-227-Like Benzoxazoles to Human α-Synuclein and Amyloid β Peptide FibrilsEmerging PET Radiotracers and Targets for Imaging of Neuroinflammation in Neurodegenerative Diseases: Outlook Beyond TSPO[F]THK-5351 PET imaging in early-stage semantic variant primary progressive aphasia: a report of two cases and a literature review
P2860
Q41454666-E6271F58-D6DB-4EEC-BD9A-24A3B06193ECQ42361526-3EAC3CCC-F128-4CB4-834D-A1A6473A1185Q42701971-0208A2C8-95C3-4603-AB58-931CE67E6545Q46616293-15B75244-6FB3-4809-B37D-AB69CC458D92Q46753514-67C3CD68-B9D0-440B-B121-996ADCD6B10FQ47140361-52A56C2A-1C61-4E8C-A95E-75ABC60CE5DEQ47254408-2826D513-24A0-41EB-BF97-4C94D7FB64DAQ47329627-31EBB027-1736-4F22-9471-BD5F2A3A952CQ47659524-36FCF983-4C61-4CDF-88D0-61E3B669D1D6Q47684719-ACED366B-0B56-4FE8-A277-46EE6AB4A633Q47739900-A1DA67D9-E1D9-4D0B-B170-7B58C72FD0F2Q47835964-62BA3C23-6F59-4383-B47D-CE4027B89823Q47870437-D39B0970-87A7-4E5D-9D96-573ABA5B15E1Q47918679-DFE8CED5-6EBC-4388-B4B8-9BB51DCA1193Q47926474-03ABC50F-1916-4478-A6CB-F12D0AF44CFEQ49295547-4BF49872-3AF9-4490-B2F4-8153C3F7EE15Q50042841-A99B27DF-E74C-48D9-9FDB-4BC58AB04648Q50061690-53D157C2-55B6-4741-A571-DACC0F85C2E9Q50350781-D7CF3598-577E-4C8D-A3FE-5FEB2557B60BQ51765788-920358E2-8C77-4675-B0D1-2294F31484EAQ51766173-9BBC983A-CC9B-476F-B853-3C0BC97EFF17Q51800676-094D640A-DF9A-4288-A7A8-CEDA160B5B39Q55020340-0E49A82A-1256-4ADF-8617-727023346FDBQ55031324-D9603B32-BA94-4261-8B3E-DD9F89048161Q55254017-AFD2CE50-253E-4EA2-889A-091BCA93ABEDQ55339752-DF04F1B1-920A-426F-8C53-7C3AFE460F4FQ55344088-50938F67-7723-4A6A-B217-E8230B2D3175Q55359027-F1EBFB27-0755-4F7F-A881-C459D8AA7823Q55416644-E5D14789-36E2-4646-BD7F-0EEF2F801914Q55494083-D4C83CA3-9A16-4CE3-BB80-7DC7816A7FAEQ55497377-AC358EE6-423F-4E8F-BE7A-D20539B2530FQ56594907-E34A98E1-32ED-488D-B3C1-97565D010F7EQ57040143-BB0BE5DA-458D-4FF1-8338-70F76588DC6BQ57168250-6B093CC4-C6F9-422E-B75C-002D04C51133Q57817897-7D43F41F-47AB-4C63-A24A-3DC8BC59D615Q58740165-C8230006-2253-4B3F-91B8-C59F5EB50EF1Q58751451-34099B60-B133-46A0-BBC7-2BABCA0E9C74Q58794629-8D89A473-A408-4F69-8A04-E193A68A16B8
P2860
Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 March 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain.
@en
Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain.
@nl
type
label
Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain.
@en
Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain.
@nl
prefLabel
Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain.
@en
Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain.
@nl
P2093
P2860
P50
P1476
Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain.
@en
P2093
Gassan Massarweh
Jean-Paul Soucy
Joseph Therriault
Kok Pin Ng
Marie-Christine Guiot
Min Su Kang
Monica Shin
Nobuyuki Okamura
Ryuichi Harada
P2860
P2888
P356
10.1186/S13195-017-0253-Y
P407
P577
2017-03-31T00:00:00Z
P6179
1084252361